Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have earned an average rating of “Moderate Buy” from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $5.17.

SGMO has been the topic of a number of recent research reports. Truist Financial reduced their target price on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday. Barclays boosted their target price on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Sangamo Therapeutics in a research report on Thursday, January 2nd. StockNews.com cut shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 24th. Finally, Jefferies Financial Group cut their price target on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, December 31st.

Hedge Funds Weigh In On Sangamo Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of SGMO. Meritage Portfolio Management lifted its holdings in Sangamo Therapeutics by 8.6% in the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 6,740 shares during the last quarter. Shelton Wealth Management LLC acquired a new stake in Sangamo Therapeutics in the 4th quarter valued at about $29,000. Wealth Enhancement Advisory Services LLC lifted its holdings in Sangamo Therapeutics by 55.4% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 38,850 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Sangamo Therapeutics by 5.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company’s stock valued at $956,000 after acquiring an additional 57,125 shares during the last quarter. Finally, XTX Topco Ltd lifted its holdings in Sangamo Therapeutics by 167.8% in the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 64,981 shares during the last quarter. Institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Stock Performance

Sangamo Therapeutics stock opened at $1.16 on Friday. Sangamo Therapeutics has a 1 year low of $0.30 and a 1 year high of $3.18. The firm has a 50 day moving average price of $1.81 and a 200 day moving average price of $1.31. The company has a market cap of $242.03 million, a price-to-earnings ratio of -1.55 and a beta of 1.29.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.07. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The firm had revenue of $49.41 million during the quarter, compared to the consensus estimate of $26.55 million. During the same period in the previous year, the firm earned ($0.34) earnings per share. Sell-side analysts predict that Sangamo Therapeutics will post -0.47 EPS for the current year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.